October 29, 2025 a 07:43 am
TECH: Fundamental Ratio Analysis - Bio-Techne Corporation
Bio-Techne Corporation presents a moderately promising investment opportunity, positioned within the expanding life science tools and diagnostics sector. Despite certain fiscal constraints in terms of debt and earnings, their pioneering advancements in biotechnology offer long-term potential. Investors might find value in the company's sustained innovation and strategic market placement.
Fundamental Rating
Bio-Techne Corporation holds a fundamental rating of C+, reflecting areas of both strength and improvement. Key metrics have been analyzed to provide a holistic view of the company's performance.
| Metric | Score | Visualization |
|---|---|---|
| Discounted Cash Flow (DCF) | 3 | |
| Return on Equity (ROE) | 2 | |
| Return on Assets (ROA) | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings (P/E) | 1 | |
| Price to Book (P/B) | 2 |
Historical Rating
Comparing historical data highlights consistent performance and pinpoint areas crucial for growth and improvement within the company.
| Date | Overall | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-10-28 | 2 | 3 | 2 | 4 | 1 | 1 | 2 |
| Previous Data | 0 | 3 | 2 | 4 | 1 | 1 | 2 |
Analyst Price Targets
Current analyst estimates suggest a consistent price trajectory, positioning BIO-TECHNE as a relatively stable investment option.
| High | Low | Median | Consensus |
|---|---|---|---|
| 73 | 73 | 73 | 73 |
Analyst Sentiment
The sentiment among analysts is predominantly optimistic, with a strong recommendation towards buying the stock.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 18 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Bio-Techne Corporation, leveraging its extensive capabilities in biotechnology, showcases potential for long-term growth. The stability in targeted price levels, combined with robust analyst sentiment, underscores an optimistic view. However, attention should be paid to fundamental weaknesses such as debt levels and valuation metrics. Prospective investors should consider the balance of innovation and financial diligence in deciding their positions. Overall, it remains a nuanced pick within the tech-driven healthcare industry.